[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112014011535A2 - método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo - Google Patents

método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo

Info

Publication number
BR112014011535A2
BR112014011535A2 BR112014011535A BR112014011535A BR112014011535A2 BR 112014011535 A2 BR112014011535 A2 BR 112014011535A2 BR 112014011535 A BR112014011535 A BR 112014011535A BR 112014011535 A BR112014011535 A BR 112014011535A BR 112014011535 A2 BR112014011535 A2 BR 112014011535A2
Authority
BR
Brazil
Prior art keywords
vitro
antibody
amount
binding partner
immunological determination
Prior art date
Application number
BR112014011535A
Other languages
English (en)
Inventor
Stubenrauch Kay-Gunnar
Wessels Uwe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014011535A2 publication Critical patent/BR112014011535A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
BR112014011535A 2011-12-19 2012-12-18 método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo BR112014011535A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11194350 2011-12-19
PCT/EP2012/075991 WO2013092611A2 (en) 2011-12-19 2012-12-18 Method for the detection of free binding partner of a multispecific binder

Publications (1)

Publication Number Publication Date
BR112014011535A2 true BR112014011535A2 (pt) 2017-05-09

Family

ID=47429825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011535A BR112014011535A2 (pt) 2011-12-19 2012-12-18 método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo

Country Status (11)

Country Link
US (1) US9671394B2 (pt)
EP (1) EP2795335B1 (pt)
JP (1) JP6203747B2 (pt)
KR (1) KR20140099277A (pt)
CN (1) CN104040350B (pt)
BR (1) BR112014011535A2 (pt)
CA (1) CA2853917A1 (pt)
HK (1) HK1201920A1 (pt)
MX (1) MX349003B (pt)
RU (1) RU2633488C2 (pt)
WO (1) WO2013092611A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
KR20140128314A (ko) * 2012-02-01 2014-11-05 에프. 호프만-라 로슈 아게 다중특이적 결합제의 결합 파트너 검출 방법
JP6226976B2 (ja) 2012-07-13 2017-11-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性結合物を検出するための方法
CN105683755B (zh) * 2013-11-05 2019-08-13 豪夫迈·罗氏有限公司 陷阱分子和检测分子的用途及其相关试剂盒和组合物
WO2015143277A1 (en) * 2014-03-20 2015-09-24 Wellstat Diagnostics, Llc Antibodies and methods for the detection of cell death
WO2016097116A1 (en) 2014-12-18 2016-06-23 Roche Diagnostics Gmbh Methods for reducing interferences
EP3655779A1 (en) * 2017-07-20 2020-05-27 CytomX Therapeutics, Inc. Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
CN109358192B (zh) * 2018-02-08 2020-05-12 中国科学院上海药物研究所 一种去除抗药抗体检测样品中游离药物的装置和方法、该装置的制备方法及应用
WO2019235420A1 (ja) 2018-06-04 2019-12-12 中外製薬株式会社 複合体を検出する方法
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
CN113811770B (zh) * 2019-05-13 2024-06-28 豪夫迈·罗氏有限公司 抑制干扰的药代动力学免疫测定
CN117805397A (zh) * 2024-02-29 2024-04-02 军科正源（北京）药物研究有限责任公司 检测游离vegf的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56128722A (en) * 1980-03-14 1981-10-08 Terumo Corp Removal of antiacetylcholinereceptor antibody and device therefor
US5219730A (en) 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
EP0243471A4 (en) 1985-10-22 1989-07-11 Cooper Lipotech Inc SOLID PHASE LIPOSOME IMMUNOANALYSIS SYSTEM.
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
IL92164A (en) 1988-11-03 1996-01-19 Igen Inc Particle-based electrochemiluminescent test method
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Luminescence test method and device based on magnetic tiny particles, containing many magnets
CA2140002A1 (en) 1992-07-13 1994-01-20 Jay Stout A chemical method for selective modification of the n- and/or c-terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
JPH11352129A (ja) * 1998-06-04 1999-12-24 Mizuho Medeii:Kk 検出装置及び検出方法
US6753189B1 (en) * 1998-06-04 2004-06-22 Mizuho Medy Co., Ltd. Detection apparatus and method for the same
KR100749982B1 (ko) * 1999-11-16 2007-08-16 제넨테크, 인크. 혈관 내피 성장 인자용 ｅｌｉｓａ
EP1288308A1 (en) * 2001-08-28 2003-03-05 Roche Diagnostics GmbH A method for the determination of multiple analytes
GB0320459D0 (en) * 2003-09-01 2003-10-01 Selective Antibodies Ltd Assay methods and materials
DE102004052729A1 (de) * 2004-10-30 2006-05-04 Roche Diagnostics Gmbh Immunkomplex-spezifsicher Antikörper zur Reduktion des Nullwerts beim Nachweis von Antigen-spezifisch gebundenen Antikörpern einer bestimmten Immunglobulinklasse in Array-Testformaten
CA2597996A1 (en) * 2005-03-08 2006-09-14 Tanox, Inc. Methods for determining the bivalency of protein and antibody therapeutics
CN103454434B (zh) * 2006-10-04 2016-08-10 健泰科生物技术公司 针对vegf的elisa
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
MX2011011925A (es) 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN102207054B (zh) 2010-03-31 2013-03-13 比亚迪股份有限公司 一种混合动力车的爆震控制系统及方法
CN102207504A (zh) * 2011-03-23 2011-10-05 北京华创远航科技有限公司 一种酶联检测试剂盒及其制备方法

Also Published As

Publication number Publication date
MX2014007095A (es) 2014-07-22
HK1201920A1 (zh) 2015-09-11
RU2633488C2 (ru) 2017-10-12
EP2795335B1 (en) 2017-09-06
JP6203747B2 (ja) 2017-09-27
JP2015502547A (ja) 2015-01-22
US20150072359A1 (en) 2015-03-12
CN104040350A (zh) 2014-09-10
RU2014128510A (ru) 2016-02-10
CN104040350B (zh) 2016-05-18
WO2013092611A3 (en) 2013-10-17
CA2853917A1 (en) 2013-06-27
US9671394B2 (en) 2017-06-06
MX349003B (es) 2017-07-06
EP2795335A2 (en) 2014-10-29
WO2013092611A2 (en) 2013-06-27
KR20140099277A (ko) 2014-08-11

Similar Documents

Publication Publication Date Title
BR112014011535A2 (pt) método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo
NO2023024I1 (no) Spesolimab, an ant-IL-36R antibody
CY2020045I1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
BR112014030278A2 (pt) anticorpo, e, composição.
HK1201851A1 (en) Antibodies specific for trop-2 and their uses trop-2
CR20130677A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
ZA201207211B (en) Antibodies with ph dependent antigen binding
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
EP2681239B8 (en) Antigen binding proteins
EP2821415A4 (en) ANTI-LIPOARABINOMANNAN ANTIBODIES AND IMMUNODOSIS FOR MYCOBACTERIOSIS USING SAID ANTIBODY
BR112014011304A2 (pt) anticorpos de ligação com albumina e fragmentos de ligação dos mesmos
GB201115529D0 (en) Antibodies, uses and methods
BR112012030311A2 (pt) anticorpo
GB201115280D0 (en) Antibodies, uses and methods
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
EP2525813A4 (en) ANTIBODIES TO ILT5 AND ILT5 BINDING ANTIBODY FRAGMENTS
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
DK2885639T3 (da) Kompleksspecifikke antistoffer og antistoffragmenter og deres anvendelse
BR112012016229A2 (pt) método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
SG11201402709WA (en) Method and device for assaying an antigen present on erythrocytes or an antibody binding to an antigen present on erythrocytes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]